BioAmber files for $150M IPO

In Minnesota, BioAmber has filed an S-1 registration statement for a proposed $150 million initial public offering. The number of shares to be offered and the price range for the offering have not yet been determined.

The lead book-running managers for the offering are Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC. The additional book-running manager is Barclays Capital. The co-managers are Stifel, Nicolaus & Company, Incorporated and Pacific Crest Securities LLC.

The company is currently ranked #143rd in the world in the 50 Hottest Companies in Bioenergy. The rankings recognize innovation and achievement in fuels and are based on votes from a panel of invited international selectors, and votes from Digest subscribers.

BioAmber becomes the 13th company to file for an IPO in the industrial biotech boom, which began with a successful listing on the NASDAQ by Codexis in 2010. IPOs by Amyris, Gevo, Solazyme, and KiOR have followed. In recent months, PetroAlgae, Myriant, Ceres, Genomatica, Mascoma, Elevance Renewable Sciences and Fulcrum Bioenergy have also filed S-1 registrations for proposed IPOs.

The complete S-1 registration statement is here.

The Digest will publish its “BioAmber’s $150M IPO: The Ten-Minute Version” on Tuesday, November 15th by 9AM Eastern time.